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ABSTRACT 
Chinnasamy, Swathee. M.S., Microbiology and Immunology 
Program, Wright State University, 2011. Developing a 
quantitative PCR assay for detecting viral vector 
shedding from animals. 
 
 
 
 
Replication deficient viruses have been used widely 
for replacing, repairing, and deleting target genes. 
These recombinant viruses are tested on research animals 
or patients in clinical trials. Although viral vectors 
distribute in the body, they are also disseminated into 
the environment through secretion and excretion 
processes. By studying the extent of shedding, a proper 
risk assessment can be performed and appropriate 
biocontainment can be achieved. 
Adenoviral and lentiviral vectors were produced from 
commercially available kits. The transgene present in 
both vector systems was the lacZ reporter gene encoding 
for β-galactosidase. Primers and probes were designed for 
the encapsidation region of the adenoviral vector and the 
Rev Response Element (RRE) of the lentiviral vector to 
 
 iv 
 
detect the viral vectors by Q-PCR. Internal control 
sequences were also designed and synthesized for both 
systems. Standard curves were generated using five 10-
fold serial dilutions. Singleplex reactions confirmed the 
specificity of the probes on the viral DNA and the 
quality control sequences. A comparison of singleplex 
with multiplex data was performed to validate the assay. 
The assay was used to quantify the total virus genome 
count (vg) present in adenoviral and lentiviral stocks. 
The vg counts were compared to the infectious titers in 
order to gauge the quality of the virus stocks. For the 
lentivirus stock, a second confirmatory assay was made by 
p24 assay using enzyme linked immunosorbent assay to 
validate the Q-PCR results. The efficiency of cDNA 
synthesis (to convert the lentiviral RNA into cDNA for Q-
PCR) was determined to be 20% on average. 
Overall, a highly specific and sensitive Q-PCR assay 
was developed that will enable researchers to quantify 
the amount of adenoviral and lentiviral vector shedding 
from infected animal hosts. This assay will help to 
determine proper housing requirements for research 
animals and improve worker safety. 
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II. INTRODUCTION: 
Gene therapy is a potential form of treatment for a 
variety of acquired and inherited diseases. The therapy 
involves introducing genetic material into target cells to 
slow a disease process or cure a particular condition. The 
treatment is accomplished by using gene transfer vectors 
that can 1ittering1 different cells, organs, or tissues.  
Vectors can be engineered to possess a variety of 
desirable characteristics, such as having the ability to be 
produced in large quantity and concentrated form, to 
1ittering1 different cell types (both dividing and non-
dividing cells), to be stably expressed (either by 
integration into host DNA or by formation of an episome), 
and to avoid unwanted immune responses. 
Gene delivery may be classified into two categories: 
non-viral and viral. The non-viral gene delivery methods 
include chemical transfection, lipofection, or 
electroporation of naked DNA. Although naked DNA vectors 
have the advantage of being produced in high concentration 
and eliciting less immune response, they suffer from 
transient gene expression and inefficient gene transfer. 
 
2 
 
Viral vectors provide a more efficient way of 
transferring a desired gene into target cells since they 
have naturally evolved to deliver their own RNA or DNA 
genomes into host cells (Verma & Weitzman, 2005). In 
general, viruses are capable of inserting their genetic 
material into host cells for replication and have evolved 
over time to escape host immune responses. One strategy for 
gene therapy is to replace some of the viral genes with the 
desired foreign genes (transgenes) and to engineer the 
virus to 2ittering2 a desired target cell population. Some 
viruses that are commonly used as vectors include 
adenovirus, lentivirus, retrovirus, adeno-associated virus, 
and herpes simplex virus (Warnock, Daigre, & Al-Rubeai, 
2011). 
  
Adenovirus as a vector: 
Adenoviruses represent the largest non-enveloped 
viruses, having achieved the largest size that can be 
transported via endosomes. The virus structure is comprised 
of an icosahedral capsid and double-stranded DNA genome of 
about 26-45 kb (Volpers & Kochanek, 2004). Adenovirus was 
originally isolated in 1953 from adenoid tissue. Since 
then, more than 50 serotypes have been discovered and also 
classified into six species A-F (Warnock et al., 2011). 
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They cause upper respiratory diseases, bladder infections, 
and gastroenteritis, depending on the serotype.  
Adenovirus capsids have a pentameric penton base 
protein from which the trimeric fiber protein extends into 
a globular knob domain. The virus attaches to its cellular 
receptor using the globular knob domain of the fiber 
protein (Volpers & Kochanek, 2004). Depending on the 
serotype, adenoviruses use a variety of cellular receptors, 
including the Coxsackie-Adenovirus receptor, other 
immunoglobulin superfamily proteins, integrins, 3itteri 
sulfate glycosaminoglycans, cluster of differentiation 
antigens, sialic acid, and other proteins and non-protein 
molecules (Zhang & Bergelson, 2005). The 
arginylglycylaspartic acid tripeptide (RGD) motif in the 
penton base protein interacts with surface integrin 
molecules of the cell, leading to internalization of the 
virus by means of clathrin-dependent receptor mediated 
endocytosis. Following the internalization of the virus, 
the capsid is dismantled in the cytoplasm and the core 
protein-coated viral genome is transported in to the 
nucleus (Russell, 2009). 
The Adenovirus genome consists of two regions for 
transcription—the early and the late regions. The early 
region contains four transcription units. The first gene 
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transcribed is E1A, which codes for a transactivator 
protein for the other early region genes, E1B, E2, E3 and 
E4. The E2 gene codes for DNA polymerase, preterminal 
protein, and DNA binding protein, which are required for 
viral replication. The E3 region encodes for proteins that 
have anti-immune functions. The E4 region encodes for 
proteins involved in mRNA transport and splicing (Warnock 
et al., 2011). Adenovirus type 5 (Ad5) is the most commonly 
used serotype for vector design. First generation vectors 
have the E1 and E3 genes deleted, thus preventing the virus 
from replicating and providing space for foreign gene 
insertion. Since the E1 gene is essential for replication, 
the vectors must be complemented. This is generally 
accomplished by using the human embryonic kidney cell line 
named 293, which expresses E1 proteins (Bett et al., 1994). 
This system allows for high titers to be produced, but the 
lack of E3 causes the virus to be cleared from the system 
due to the host immune response, thus leading to short 
duration of transgene expression. A major limitation of 
adenoviral vectors it is that they induce inflammation, are 
neutralized by host antibodies, and exhibit short term 
expression of transgenes (Kovesdi et al., 1997). 
 Two approaches have been traditionally used to 
generate recombinant adenovirus vectors. The first method 
 
5 
 
has been to directly ligate the gene of interest into the 
adenoviral genome. This method turned challenging as the 
virus is large and there were not many unique restriction 
sites. Another approach was developed where the gene of 
interest is cloned into a shuttle vector followed by 
transferring the gene into the virus genome via homologous 
recombination in mammalian packaging cell lines. The 
disadvantage here is that defective adenovirus was 
produced, and the screening and purification of plaques and 
repeated purification was laborious (Mittal et al. 1993; 
Stratford-Perricaudet, et al. 1992). 
 Later, a method to reduce the time consumption for 
producing a recombinant adenovirus was introduced that 
utilized the homologous recombination carried out in 
prokaryotic cells (bacteria), giving a better selection 
system (He et al., 1998). The recombinant adenovirus is 
produced by a double recombination process between a 
plasmid vector, which has an adenoviral backbone, and a 
shuttle vector, which carries the gene of interest. To 
avoid the background caused by non-recombinant shuttle 
plasmid, the bacteria are pre-transformed with the plasmid. 
The recombinant adenovirus is selected by resistance to 
antibiotic. The recombinant adenovirus is then packaged in 
mammalian cell lines which complement with the E1 gene in 
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trans that is required for replication. This system has 
been commercialized by Agilent Technologies (formerly 
Stratagene) as the AdEasyTM system. 
 
Lentivirus as a vector: 
Although retroviruses in the Gammaretrovirus genus of 
the Retroviridae family had been used widely for delivering 
genes into target cells, they had the disadvantage of not 
being able to infect the non-dividing cells. When it was 
discovered that viruses in the Lentivirus genus of the 
Retroviridae family contained nuclear localization signals 
on the Matrix, Vpr, and Integrase proteins that allow them 
to cross the nuclear membrane in the absence of mitosis, 
interest grew in developing lentiviral vectors for gene 
delivery. 
One of the most commonly studied lentiviruses is HIV-
1. Some of the other lentiviruses include Bovine 
immunodeficiency virus (BIV), Simian immunodeficiency virus 
(SIV) and Feline immunodeficiency virus (FIV). The genome 
organization of HIV-1 is similar to that of other 
retroviruses, but it has additional regulatory and 
accessory genes that lead to a more complex replication 
cycle. Its RNA genome is about 10 kb and its capsid is 
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about 100 nm in diameter (Volpers et al., 2004). The HIV-1 
regulatory proteins are Tat and Rev. The former helps the 
viral RNA to be produced by activating the viral promoter. 
The Rev protein promotes the transport of unspliced RNA 
from the nucleus to the cytoplasm by interacting with the 
Rev responsive element (RRE) present on the viral RNA. 
In general, retroviruses enter cells by fusion with 
the plasma membrane. The exact mechanism of uncoating is 
unclear. Reverse transcription takes place in the 
cytoplasm, and the double-stranded DNA intermediate is 
transported to the nucleus where it integrates into the 
host chromosome. At this point, the virus is under control 
of the cellular transcription machinery. 
Many of the early HIV vectors were almost intact viral 
genomes having deletions in the env gene, which was 
provided in trans. Use of the wild-type HIV Env limited the 
target cell population to CD4+ cells. Replacing the HIV Env 
with other viral envelope proteins (such as VSV-G, MLV 
amphotropic envelope glycoprotein) resulted in a wider 
target of cell types and higher titer values. 
 The chances of producing a replication competent 
virus was reduced by producing the second and third 
generation vectors and also the self inactivating 
 
8 
 
lentivirus vector (SIN) (Dull et al., 1998; Miyoshi et al., 
1998; Zufferey et al., 1998). Separate plasmids were used 
in all these vector systems for envelope genes and 
packaging genes, but the third generation system uses a 
fourth plasmid encoding the rev gene in addition to the 
above features. The third generation vectors had the Tat 
dependent promoter replaced with Rous sarcoma virus (RSV) 
promoter. Thus, the most widely used lentiviral vectors are 
the third generation vectors since they reduce the sequence 
homology with the wild type HIV (Dull et al., 1998). 
 
Biodistribution of Adenoviral and Lentiviral vectors: 
 Therapeutic effect is achieved on a pathological 
process by means of gene transfer to a target tissue. 
Possible expression of the transgene in non-target tissue 
is a drawback for gene therapy. One of the main 
characteristic features to be studied for a vector used in 
gene therapy is biodistribution in tissues (Pan et al., 
2002). Biodistribution study aims at defining areas where 
the vector spreads, target organs for toxicity, and 
germline transmission risk assessment. Some of the commonly 
studied organs are heart, brain, liver, spleen, kidney, 
lungs. One of the most widely used methods to detect 
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toxicity based on genetic material transferred is 
quantitative PCR (Q-PCR). Prior to clinical trial, these 
studies are generally conducted on cell lines and in animal 
models (Hiltunen et al., 2000).    
 Adenoviral vector biodistribution has been 
studied previously, and it was found to be predominantly 
expressed in the liver when injected into mice through 
intravenous route (IV, tail vein injection) (Alemany, et 
al. 2000; Wood et al., 1999). The IV route also resulted in 
expression in most organs, including the lung, kidney, 
heart, and spleen. A study involving the distribution of 
the human-multi drug resistance gene (MDR1) was evaluated 
using the mice colon carcinoma model, in which the 
adenovirus was administered by bone marrow transplantation. 
By means of in situ hybridization and immunohistochemistry, 
they demonstrated that the vector was expressed in the 
lung, kidney, intestine, and bone marrow cells, and not in 
the liver, spleen, brain, or tumor (Zhao et al., 2010).  
Hiltunen et al. (2000) showed that biodistribution 
depended on the route of administration. They administered 
adenovirus vector virus to rabbits through periadventitial 
and intravascular routes and showed that both methods lead 
to systemic leakage of virus and expression in non-target 
organs such as the bone marrow, liver, skeletal muscle, and 
 
10 
 
testis. Less leakage was observed with the periadventitial 
delivery route. Biodistribution is followed by shedding and 
the data for both are required for analyzing the safety 
profile (Tiesjema, et al. 2010). 
 
Shedding via Excretion: 
 The dissemination of viral vector into the environment 
by means of excreta is referred as shedding. It is 
considered a major risk factor to the environment and 
therefore shedding analysis of urine and feces are 
performed. Again, shedding depends on the route of 
administration since it leads to biodistribution to those 
organs from where it sheds. Three possible routes have been 
studied for shedding via urine and they are through blood 
and kidney, from bladder and from prostrate through the 
ureter. Biodistribution of the virus to the liver and 
secretion of bile remains as a possible route for shedding 
via feces. Kawahira et al (2009), in their analysis of 
adenoviral shedding after esophagus cancer treatment, 
showed that 29.7% percentage of patients were positive for 
shedding via feces and also 10% patients showed positive 
for shedding via urine, suggesting that gastrointestine can 
be a possible route for shedding. Treatment of lung cancer 
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with adenoviral vector also showed positive stool samples 
(Griscelli et al., 2003). The I.V route leading to 
biodistribution to kidney acts as a possible route for 
adenoviral vector shedding through urine and other routes 
include intra-prostatic and intramuscular. (Tiesjema et 
al., 2010). 
 Quantification of the shedding is performed using Q-
PCR. Some of the other methods include conventional PCR and 
transgene expression. In case of patients treated with 
viral vectors the potential for transmission to third 
parties needs to be considered if shedding is observed. 
Other factors to be considered are that shedding is time 
and dose dependent. One of the most important parameters 
for performing successful Q-PCR is the use of a control, 
which is sometimes spiked into the actual test sample, for 
checking inhibition, specificity, and sensitivity of the 
reaction. Reactions for Q-PCR are often performed in 
duplicate or triplicate to increase accuracy (Gonin & 
Gaillard, 2004). The technique of using an internal control 
in the same reaction tube (multiplexing) offers the 
advantage of greater accuracy, but this control can also 
compete against the amplification, if not chosen carefully 
and validated.  
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III. MATERIALS AND METHODS: 
Vector production: 
Adenoviral vector: 
 The Ad EasyTM XL Adenoviral vector system (Agilent 
Technologies, Santa clara, CA) was used for the production 
of adenoviral vector using the manufacturer’s instruction. 
The following is a brief description of the protocol. 
 The pshuttle-CMV-lacZ vector encoding the gene for β-
galactosidase was linearized with the enzyme PmeI (New 
England Biolabs, Ipswich, MA) and transformed into BJ5183-
AD-1 competent cells and plated. The smallest colonies were 
chosen. DNA was isolated, checked for the desired size, and 
transformed into the XL-10 Gold cells for amplification of 
the plasmid. Individual colonies from the transformation 
reaction were selected and restricted with PacI (New 
England Biolabs) and analyzed for the correct restriction 
pattern. A maxi prep (QIAGEN, Valencia, CA) was performed 
to isolate a large amount of plasmid DNA from a large 
culture, and it was stored at 4°C. Plasmid DNA for 
transfection was restricted PacI (New England Biolabs, 
Ipswich, MA) and purified using the StrataPrep PCR 
Purification Kit (Agilent Technologies). The AD-293 cell 
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line was established and passaged as per the manufacturer’s 
instruction. This cell line was used for transfection of 
the recombinant Ad5 plasmid to produce recombinant 
adenovirus. The primary viral stocks were produced, stored 
at -70°C, and 13itterin using a plaque assay. A second 
round of infection was performed on the cells to amplify 
the viral stock which was then purified and concentrated on 
a binding column using the AdEasy Purification kit (Agilent 
Technologies). The stocks were 13itterin again using plaque 
assay.   
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              Linerarized with PmeI  
 
      Transformed into of BJ-5183-AD-1 cells       
                           Homologous recombination occurs 
  Amplification of recombinant DNA with XL-10 gold cells     
  
DNA digested with PacI to give linearized recombinant DNA 
 
                Ad-293 cells transfected 
 
         Virus produced, followed by titering virus                    
Fig 1: An outline of the steps involved in the Ad EasyTM XL 
Adenoviral vector system. 
pshuttle
-CMV-
lacZ. 
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Lentiviral vector: 
 The lentiviral (HIV) vector was produced using pLenti 
6.3/V-5 DEST kit (Invitrogen, Carlsbad, CA). The vector 
containing the lacZ gene with pLenti-DEST was transformed 
into One Shot Stbl3TM cells that were provided with the kit 
and plated. Colonies were selected and cultured for plasmid 
isolation using a mini prep kit (QIAGEN). Restriction with 
XhoI (New England Biolabs) enzyme was performed to confirm 
the presence of the correct DNA size. This DNA was used to 
transform XL-10 gold cells, selected on agar plates 
containing kanamycin, and cultured. Plasmid DNA was 
isolated by maxi prep (QIAGEN). It was restricted with XhoI 
(New England Biolabs) to confirm the restriction pattern. 
The restricted DNA was used to transfect the 293FT cell 
line along with the ViraPower Lentiviral Expression Systems 
(Invitrogen) to produce recombinant lentiviral vector 
virus. 
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             Transformed into One Shot Stbl3™ 
 
 
  DNA is amplified by transformation into XL-10 gold cells. 
 
        Virapower packaging 
                     mix 
 
              Co-transfection of 293FT cell line 
 
 
Virus produced, followed by 16ittering the virus                                   
 
 
Fig 2: An outline of the steps involved in the pLenti 
6.3/V-5 DEST kit. 
 
pLenti 
6.3/v5-
GW/lacZ 
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Adenoviral primers and probes:  
 The wild type probe for the adenoviral vector was 
labeled at the 5ʹ end with reporter dye molecule 6-
carboxyfluorescein (6-FAM) whose emission wavelength is 520 
nm and at the 3ʹ end with Black Hole Quencher-1 with a 
quenching wavelength between 520 and 583 nm. The QC probe 
for the adenoviral vector was labeled at the 5ʹ end with 
reporter dye molecule 6-carboxyfluorescein-4’,5’-dichloro-
2’,7’-dimethoxyfluorescein (JOE) whose emission wavelength 
is 555 nm and at the 3ʹ end with Black Hole Quencher-2 with 
a quenching wavelength between 550 and 668 nm. For 
detection of the encapsidation region which starts at 183 
bp in the adenoviral vector, the primers were designed 
using MacVector software to yield a final amplicon of 116 
bp.  
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TABLE 1: SEQUENCE INFORMATION OF PRIMERS/PROBES USED FOR 
ADENOVIRAL VECTOR. 
 
 
 
PRIMER/PROBE SEQUENCE NUMBER OF 
BASEPAIRS 
MELTING 
TEMPERATURE 
FORWARD 
PRIMER 
5ʹ-ACA GGA AGT GAC AAT 
TTT CGC-3ʹ 
   21 66.0°C 
REVERSE 
PRIMER 
5ʹ-TCA GAT TTC ACT TCC 
TCT TAT TCA G-3ʹ 
   25 64.69°C 
PAdEASY WT 
PROBE 
5ʹ-/56-FAM/ACT CGG TTA 
CGC CCA AAT TTA CTA 
CAA CAT/3BHQ -1/-3ʹ 
   30 71.62°C 
CONTROL 
SEQUENCE 
PROBE 
5ʹ-/56-JOEN/ ACT ATG 
CCA CGC TCA CAT GTA 
TTA CAT CGT/3BHQ-1/-3ʹ 
   30 72.65°C 
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                          Encapsidation Start 
                          | 
       166       176      |186       196       206       216       226  
         *         *      |  *         *         *         *         * 
GATGTGGCAAAAGTGACGTTTTTGGTGTGCGCCGGTGTACACAGGAAGTGACAATTTTCGCGCGGTTTTA 
CTACACCGTTTTCACTGCAAAAACCACACGCGGCCACATGTGTCCTTCACTGTTAAAAGCGCGCCAAAAT 
 
 
       236       246       256       266       276       286       296 
         *         *         *         *         *         *         * 
GGCGGATGTTGTAGTAAATTTGGGCGTAACCGAGTAAGATTTGGCCATTTTCGCGGGAAAACTGAATAAG 
CCGCCTACAACATCATTTAAACCCGCATTGGCTCATTCTAAACCGGTAAAAGCGCCCTTTTGACTTATTC 
 
 
       306       316       326       336 
         *         *         *         * 
AGGAAGTGAAATCTGAATAATTTTGTGTTACTCATAGCGCGTAA 
TCCTTCACTTTAGACTTATTAAAACACAATGAGTATCGCGCATT 
                                  |   
                                  | 
                                  Encapsidation End 
 
 
 
Fig 3: Sequence of Wild Type adenoviral encapsidation region. 
The sequence of the encapsidation region on the adenoviral vector for which the primers 
and probe were designed. Sequences in red : forward and reverse primers and the probe 
sequences are double underlined.
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                          Encapsidation Start 
                          | 
       166       176      |186       196       206       216       226  
         *         *      |  *         *         *         *         * 
GATGTGGCAAAAGTGACGTTTTTGGTGTGCGCCGGTGTACACAGGAAGTGACAATTTTCGCGCGGTTTTA 
CTACACCGTTTTCACTGCAAAAACCACACGCGGCCACATGTGTCCTTCACTGTTAAAAGCGCGCCAAAAT 
 
 
       236       246       256       266       276       286       296 
         *         *         *         *         *         *         * 
GGCGGACGATGTAATACATGTGAGCGTGGCATAGTAAGATTTGGCCATTTTCGCGGGAAAACTGAATAAG 
CCGCCTGCTACATTATGTACACTCGCACCGTATCATTCTAAACCGGTAAAAGCGCCCTTTTGACTTATTC 
 
 
       306       316       326       336 
         *         *         *         * 
AGGAAGTGAAATCTGAATAATTTTGTGTTACTCATAGCGCGTAA 
TCCTTCACTTTAGACTTATTAAAACACAATGAGTATCGCGCATT 
                                  |   
                                  | 
                                  Encapsidation End 
 
 
 
Fig 4: Sequence of Adenoviral vector Synthetic Fragment (Quality Control). 
The sequences in red indicate the forward and reverse primers; the probe sequences are 
double underlined and the mutated base pairs are indicated in BOLD. This entire region 
was inserted into pIDTSMART (Integrated DNA technologies, San Jose, CA).
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Lentiviral primers and probes: 
 Similar to the adenovirus system, the probe for the 
wild type lentiviral vector was labeled at the 5ʹend with 
6-FAM and at the 3ʹ end BHQ-1, whereas the probe for the 
lentiviral QC sequence was labeled at the 5’ end with JOE 
and at the 3’ end with BHQ-2. The region for detection was 
the Rev Responsive Element (RRE) starting at 1075 bp of the 
lentiviral vector. For detection of the HIV RRE region, 
which starts at 1075 bp in the HIV vector, the primers were 
designed using MacVector software to yield a final amplicon 
of 111 bp.  
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TABLE 2: SEQUENCE INFORMATION OF PRIMERS/PROBES USED FOR 
LENTIVIRAL VECTOR. 
PRIMER/PROBE SEQUENCE NUMBER OF 
BASEPAIRS 
MELTING 
TEMPERATURE 
FORWARD 
PRIMER 
5ʹ-TCA ATG ACG CTG 
ACG GTA C-3ʹ 
   19  65.28°C 
REVERSE 
PRIMER 
5ʹ /GAC TGT GAG TTG 
CAA CAG ATG/3ʹ 
   21  63.88°C 
p Lenti RRE 
WT PROBE  
5ʹ/56- FAM/ TGT TCT 
GCT GCT GCA CTA TAC 
CAG ACA/3BHQ- 2/3ʹ 
   27  71.84°C 
CONTROL 
SEQUENCE 
PROBE 
5ʹ/56- JOEN/TGC TCT 
ACC ACT GAA CTC TAC 
GAG TCT/3BHQ-2/3ʹ 
   27  72.26°C 
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RRE Start 
| 
|     1084      1094      1104      1114      1124      1134      1144 
|        *         *         *         *         *         *         * 
AGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCGTCAATGACGCTGACG 
TCCTCGAAACAAGGAACCCAAGAACCCTCGTCGTCCTTCGTGATACCCGCGTCGCAGTTACTGCGACTGC 
 
      1154      1164      1174      1184      1194      1204      1214 
         *         *         *         *         *         *         * 
GTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAATTTGCTGAGGGCTATTGAGGCGC 
CATGTCCGGTCTGTTAATAACAGACCATATCACGTCGTCGTCTTGTTAAACGACTCCCGATAACTCCGCG 
 
      1224      1234      1244      1254      1264      1274      1284 
         *         *         *         *         *         *         * 
AACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAGGCAAGAATCCTGGCTGTGGAAAG 
TTGTCGTAGACAACGTTGAGTGTCAGACCCCGTAGTTCGTCGAGGTCCGTTCTTAGGACCGACACCTTTC 
 
                       RRE End 
      1294      1304   | 
         *         *   | 
ATACCTAAAGGATCAACAGCTCCT 
TATGGATTTCCTAGTTGTCGAGGA 
 
Fig 5: Sequence of Wild Type HIV RRE region. The sequence of the RRE region on the 
lentiviral vector for which the primers and probe were designed. Sequences in red : 
forward and reverse primers and the probe sequences are double underlined.
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RRE Start 
| 
|     1084      1094      1104      1114      1124      1134      1144 
|        *         *         *         *         *         *         * 
AGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCGTCAATGACGCTGACG 
TCCTCGAAACAAGGAACCCAAGAACCCTCGTCGTCCTTCGTGATACCCGCGTCGCAGTTACTGCGACTGC 
 
      1154      1164      1174      1184      1194      1204      1214 
         *         *         *         *         *         *         * 
GTACAGGCCAGACAATTATAGACTCGTAGAGTTCAGTGGTAGAGCAATTTGCTGAGGGCTATTGAGGCGC 
CATGTCCGGTCTGTTAATATCTGAGCATCTCAAGTCACCATCTCGTTAAACGACTCCCGATAACTCCGCG 
 
      1224      1234      1244      1254      1264      1274      1284 
         *         *         *         *         *         *         * 
AACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAGGCAAGAATCCTGGCTGTGGAAAG 
TTGTCGTAGACAACGTTGAGTGTCAGACCCCGTAGTTCGTCGAGGTCCGTTCTTAGGACCGACACCTTTC 
 
                       RRE End 
      1294      1304   | 
         *         *   | 
ATACCTAAAGGATCAACAGCTCCT 
TATGGATTTCCTAGTTGTCGAGGA 
 
Fig 6: Sequence of HIV Synthetic Fragment (Quality Control). 
The sequences in red: forward and reverse primers; the probe sequences are double 
underlined and the mutated base pairs are indicated in BOLD. This entire region was 
inserted into pIDTBLUE (Integrated DNA Technologies). 
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Quality control (QC) sequences:  
Quality control sequences were designed for both adenoviral 
and lentiviral vectors by incorporating specific mutations 
into the probe region of the synthetic molecule to allow 
differential detection in PCR. Restriction sites NcoI and 
PstI for adenoviral and XhoI and NotI for lentiviral 
control sequence were engineered at the ends of the 
synthetic molecules for cloning. The adenoviral QC sequence 
was cloned into the pIDTSMART vector, while the lentiviral 
QC sequence was cloned into pIDTBlue vector (Integrated DNA 
Technologies), the latter being an in vitro transcription 
vector. 
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A) 
B)             
                    
Fig 7: Quality control sequence inserted into plasmids by 
IDT. 
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 Region in Blue is the QC sequence flanked by restriction 
sites A) QC plasmid for adenoviral vector; B) QC plasmid 
for lentiviral vector. 
 
RNA production and isolation: 
 The lentiviral QC sequence was in vitro transcribed 
using the RiboMAX Large Scale RNA Production System 
(Promega, Madison, WI). The pIDTBlue vector DNA containing 
the lentiviral QC sequence was extracted with a 
phenol:chloroform mixture to enhance cutting with NotI (New 
England Biolabs). The restricted DNA was separated from 
uncut DNA by overnight gel electrophoresis using constant 
amperage of 30 mA, 1.5% agarose gel, and Tris-boric acid-
EDTA buffer. The desired linearized plasmid of 3,139 bp was 
excised from the gel and purified using QIAquick extraction 
kit (QIAGEN). The in vitro transcription reaction was 
performed using the gel purified plasmid DNA, T7 
polymerase, and other RiboMAX reagents at 37°C for four 
hours. To remove input DNA, RNase-free Dnase was added at a 
concentration of one unit per microgram of input DNA and 
incubated at 37°C for 15 minutes. The RNA was purified 
using SV RNA Isolation System (Promega) following the 
manufacturer’s instructions. The purified RNA was analyzed 
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for size, purity, and concentration by electrophoresis on a 
1% native agarose gel using Tris-acetic acid, EDTA buffer. 
The RNA was further quantified by UV spectrometry, 
aliquoted, and stored at -70°C. 
 
RT-PCR: 
  The RNA was converted to cDNA using the High Capacity 
cDNA Reverse Transcription kit (Applied Biosystems, 
Carlsbad, CA) in accordance with manufacturer’s 
instructions. Serial 10-fold dilutions of the RNA were made 
such that there was a range of 1 to 106 molecules per cDNA 
reaction. The reaction conditions were 10 minutes at 25°C, 
120 minutes at 37°C, 5 minutes at 85°C and ∞ at 4°C. This 
cDNA was used in Q-PCR to determine the reverse 
transcription efficiency.  
 
Quantitative PCR (Q-PCR): 
 For quantitative PCR analysis of adenovirus and 
lentivirus genomes, primers and probes were synthesized by 
IDT (Integrated DNA Technologies). The reactions were 
performed on the ABI Prism 7900 HT sequence detection 
system under the following reaction conditions: 1 cycle at 
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50°C for 2 min, 1 cycle at 95°C for 10 min, and 40 cycles 
at 95°C for 15 sec and 60°C for 60 sec. A set of DNA 
standards were produced that corresponded to 106,105,104,103 
and 102 molecules per Q-PCR reaction. The standards were 
created by diluting the wild type and quality control 
plasmid DNAs of the Adenovirus and HIV-1 vectors. The 
dilution buffer was 10 mM Tris, 1 mM EDTA, pH 7.5. The 
final Q-PCR reaction volume was 20 µl and contained the 
proprietary TaqMan mix (Applied Biosystems, Carlsbad, CA), 
which provided all of the necessary reagents for 
amplification. Primers were used at concentrations of 18 µM 
and probes were used at concentrations of 2.5 µM. The 
graphs and statistical analyses for the standard curves 
were plotted using SigmaPlot 11.2 software (Systat Software, 
Inc., San Jose, CA). 
 
p24 Assay: 
 The p24 assay was performed using Retrotek HIV-1 p24 
Antigen ELISA kit (Zeptometrix Corporation, Buffalo, NY) by 
following the manufacturer’s protocol. 
 
 
 
 
30 
 
                    III.RESULTS 
Successful construction of Adenoviral vector: 
Generation of recombinant Ad plasmid:  
 The Ad EasyTM XL Adenoviral vector system (Agilent 
Technologies) makes use of the first generation adenoviral 
vector system. The two sets of early region genes, E1 and 
E3, are deleted in this system. The E1 region is required 
for replication of virus. However, it is provided in trans 
by the AD-293 cells. The recombinant adenoviral plasmid was 
constructed by transforming the BJ5183-AD-1 competent cells 
with linearized shuttle vector pshuttle-CMV-LacZ and pAd 
Easy vector-1. Both the shuttle vector and pAd Easy-1 have 
the right arm and the left arm regions that provide 
sequence homology for the process of homologous 
recombination. The transformed cells were plated and the 
smallest colonies were chosen and cultured. The 
recombination was confirmed by isolating the plasmid DNA, 
restricting with PacI (New England Biolabs) and loading 
onto an agarose gel to visualize a 3.0 kb band showing the 
recombination occurred between the left and right arms. 
This DNA was used for amplification of the plasmid using 
XL-10 gold cells and following a similar selection process, 
the 3.0 kb band on the gel was observed. 
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Viral Vector Production: 
 Adenovirus was produced by transfection of AD-293 
cells with plasmid DNA. After transfection of cells with 
linearized plasmid DNA, virus was harvested from cells 
after 8 days for a primary viral stock. The titer of the 
viral stock was determined by plaque assay. Cells were 
infected with serial 10-fold dilutions of virus stock in 
duplicate and overlaid with agarose. Visible plaques 
appeared after about one week, and they were counted on day 
20 post-infection. Using this primary stock, one more round 
of infection was performed to achieve an increase in viral 
titer. For this amplification, the virus was harvested 
after 24-48 hr. The viral stocks were then purified and 
concentrated by the AdEasy Purification kit (Agilent 
Technologies). To determine the titer of the stock, a 
plaque assay was again performed. Two adenovirus stocks 
were made and had titers of 6 x 107 and 4 x 108 pfu/ml. 
 
Successful construction of Lentiviral Vector: 
 The HiPerform™ Lentiviral Expression System 
(Invitrogen) was used and represents a third generation 
lentiviral vector system. It comprises four plasmids—one 
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vector and three helper plasmids. This reduces the chance 
of producing replication competent virus. The regulatory 
and accessory genes of HIV coding for as Tat, Rev, Vif, 
Vpr, Vpu, and Nef are deleted from the vector plasmid, and 
the third helper plasmid contains VSV-G (Vesicular 
stomatitis virus envelope protein) replacing the env gene 
(Dull et al., 1998). The vector, which expresses the lacZ 
gene encoding for β-galactosidase, was transformed into One 
shot Stbl3 ™ bacteria, selected, and cultured. DNA was 
isolated and restricted with AflII and XhoI to confirm 
integrity. This plasmid was used along with ViraPower™ 
Packaging Mixture (Invitrogen) to transfect 293FT cells to 
produce virus. The expression system supplies replication 
and structural proteins for producing the viral vector. 
Viral stock was obtained and its titer was determined by 
using HT1080 cells. These cells were transduced with 10-
fold serial dilutions and placed under blasticidin 
selection 48 hours post-transduction. They were stained 
with crystal violet after 10 days, and the stained colonies 
were counted. The final viral stock had a concentration of 
1 x 107 pfu/ml. 
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Assay Design: 
Primers and probes were designed from the DNA sequence 
of the adenoviral and lentiviral vectors. These primers and 
probes were designed in a manner that they can be used 
universally for the current generation of vectors. For 
adenoviral vectors, they were designed for the 
encapsidation region. For the lentiviral vector, primers 
and probes were designed in the Rev Response Element (RRE) 
region. An internal control was also designed for both the 
vectors. 
 
Generation of quality control sequence templates: 
 Quality control sequences were designed such that the 
region of probe binding in the encapsidation region of 
adenoviral vector had 10 sequence differences; the RRE 
region of lentiviral vector had 8 differences. They were 
further designed such that the melting temperatures were 
nearly identical. These sequences were cloned into two 
different plasmids for both vectors. These plasmids were 
transformed into bacteria for large scale production. The 
plasmids were serially diluted for the use as standards 
alongside the wild type standards for quantification 
purposes. 
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 The quality control sequence DNA of lentiviral vector 
was converted to RNA, since the genetic material of 
lentiviral vector is RNA. For the conversion, the DNA was 
extracted with phenol:cholorform for efficient restriction. 
It was restricted by Not I to create a 3’ end to terminate 
transcription. Insufficient cutting was observed when the 
plasmid DNA by itself was restricted using Not I and 
separated on an agarose gel. Therefore, the plasmid DNA was 
extracted twice using phenol:cholorform and then 
restricted. This resulted in more efficient cutting of the 
DNA.  The restricted DNA was loaded onto an agarose gel 
(Fig 8). The desired band was purified and transcribed into 
RNA by using RiboMAX™ Large Scale RNA Production System 
(Promega). The RNA was purified using the SV RNA isolation 
system (Promega), analyzed by agarose gel electrophroesis, 
and quantified by spectophotometry. A single RNA species of 
296 bases was produced (Fig. 9). The RNA was diluted to a 
concentration of 1 x 1011 molecules/μl, aliquoted, and 
stored at -70°C for later use as a control. 
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Fig 8: Agarose gel analysis of lentiviral quality control 
sequence DNA after restriction. 
Quality control sequence DNA of lentiviral vector 
restricted with Not I after it was extracted twice by 
phenol:choloroform. Lane 1: Uncut pLenti RRE QC DNA; Lanes 
2,4,5: Restricted pLenti RRE QC DNA showing 3.1 kb band; 
Lane 3: 1kb DNA Ladder. 
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Fig 9: Agarose gel analysis of purified RNA control. 
 
Lane 1: Low Range ss RNA Ladder; Lanes 2: Purified QC RNA; 
Lane 3: Transcriptional control (1,800 bases). 
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Generation of standards: 
 Ten-fold serial dilutions (representing 106 to 
102 molecules per microliter) of vector DNAs and the quality 
control sequences were amplified by Q-PCR in duplicate. A 
singleplex reaction was performed in which a single 
template was amplified using one set of primers/probe. The 
DNA was amplified, quantified, and compared to a known 
input number. The copy number of the DNA was equal to the 
input number and optimized as standards. Slopes between  
-3.1 and -3.6 with efficiencies of reactions between 90% 
and 110% and with R2 values between 0.990 and 1.00 were 
acceptable. 
Assay specificity: 
 The specificity of the probes was checked by 
amplifying the five serial dilutions of wild type DNA with 
QC primers/probe and the QC DNA with wild type 
primers/probe in separate wells on the plate and they were 
compared to the standards. There was no amplification in 
either of them, thus confirming their specificity.  
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Sensitivity of the assay: 
 The reactions were performed in multiplex i.e. 
the primers/probes were for both the wild-type and the 
control sequence plasmids but with only one of the 
templates (wt or QC) in the same well on the plate. The 
template was amplified and they were compared to the 
standards. There was no change in the sensitivity of the 
assay i.e. the probes did not inhibit each other. These 
reactions were checked separately for both adenoviral and 
lentiviral vectors.  
 Another multiplex reaction was performed: the 
primers/probes of both the wt and QC sequences were 
amplified with both wt and QC templates in the same well. 
Graphs were plotted showing their slopes, Ct values and 
efficiencies (Fig 10 & Fig 13). The Ct (cycle threshold) is 
the number of cycles required for the fluorescent signal to 
cross the established baseline level.  
 
Validation of the assay:  
 The singleplex and multiplex reactions were 
compared to validate the assay. Ct values for the wild type 
template of the vector from both singleplex and multiplex 
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were compared (Fig 11; Fig 14). Similarly, the Ct values of 
quality control sequence template were also compared (Fig 
12; Fig 15). The Ct difference is calculated and a value 
less than 1 was acceptable.  
 
Standard graphs for adenoviral vector: 
 The graphs indicate that the primers/probes for 
both the wild-type and control sequence are highly specific 
and the templates were optimized as standards. 
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Fig 10: Standard calibration curve of multiplex adenoviral 
vector. 
Quantitative PCR analysis for the adenoviral wild-type and 
control sequence (multiplex). Five 10-fold serial dilutions 
were used for the curve and the x-axis of the graph is the 
Ct values against the copy numbers on the y-axis. The Ct 
difference between them was less than one. The values of R2, 
efficiency and slope fall within the standard required 
number.  
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Fig 11: Standard curve of adenovirus Wild-type Sequence. 
To validate the multiplex assay format, Singleplex Vs 
Multiplex Ct values were compared for adenoviral vector 
wild-type sequence which was analyzed on Q-PCR. The 
efficiency, R2 and the slope of the wild type in singleplex 
was the same as in multiplex with their average Ct 
difference being 0.19. 
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Fig 12: Standard curve of adenovirus quality control 
sequence. 
To validate the multiplex assay format, singleplex Vs 
Multiplex Ct values were compared for adenoviral vector 
control sequence plasmid which was analyzed on Q-PCR. The 
values of R2, Efficiency and slope for QC were almost close 
numbers in both the singleplex and multiplex although the 
average Ct difference between the two was calculated to be 
0.39. 
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Standard graphs for lentiviral vector: 
 The statistics from the graph indicate high 
specificity for the primers/probes to the templates of 
wild-type and control sequence. 
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Fig 13: Standard calibration curve of multiplex lentiviral 
vector. 
Quantitative PCR analysis for the lentiviral wild-type and 
control sequence (multiplex). Five 10-fold serial dilutions 
were used for the curve and the x-axis of the graph is the 
Ct values against the copy numbers on the y-axis. The Ct 
difference between them was less than one. The values of R2, 
efficiency and slope fall within the standard required 
number.  
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Fig 14: Standard calibration curve of lentiviral vector 
Wild-type Sequence. 
To validate the multiplex assay format, singleplex Vs 
Multiplex Ct values were compared for wild-type sequence 
which was analyzed on Q-PCR. The values of R2, Efficiency 
and slope were almost the same for the wild type template 
in singleplex and multiplex with an average Ct difference 
of 0.14.  
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Fig 15: Standard curve of lentivirus QC Sequence. 
To validate the multiplex assay format, singleplex Vs 
Multiplex Ct values were compared for control sequence 
which was analyzed on Q-PCR. The values of R2, Efficiency 
and slope were close numbers in singleplex and multiplex 
and their average Ct difference between the two was 0.54. 
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Efficiency of Reverse Transcription-PCR: 
 The 10-fold serial dilutions of RNA of quality 
control sequence were converted to cDNA by using High 
capacity cDNA reverse transcription kit (Applied 
Biosystems, Carlsbad, CA). These cDNAs were amplified and 
quantified on Q-PCR with the primers/probe for the 
lentiviral vector QC. They were compared to the QC DNA 
standards (Fig 16). Five experiments were performed on five 
different days, and the efficiency of the reverse 
transcription kit ranged from 5% to 50% with an average of 
20% (Fig 17). 
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Fig 16: Standard curve of Lentiviral vector control 
sequence template-RNA.  
Comparison of Ct values for control sequence template-RNA 
that was run Singleplex. The y-axis being the number of RNA 
added before Reverse Transcription-PCR and the X-axis being 
the Ct values of cDNA amplified on Q-PCR after reverse 
transcription. The values of R2, efficiency and slope are an 
average of five different experiments. 
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Fig 17: Comparison of the DNA copy numbers obtained from 
RNA after reverse transcription-PCR. 
The output DNA copy number varied with each experiment. For 
an input of a 10000 copies the output varied from 5 to 5000 
copies. The efficiency of reverse transciption-Q-PCR ranged 
from 5%-50% with an average of ~20%. 
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Singleplex test on the recombinant adenovirus and 
lentivirus: 
 The wild-type primers/probe were tested on the 
virus stocks by lysing them. Ten-fold serial dilutions of 
the adenoviral stock were lysed using proteinase K to 
disrupt capsid protein (Ma et al., 2001). They were 
compared to the wild type template standards on Q-PCR 
giving a total virus genome count that was 5 to 12-fold 
higher than the infectious titer. 
 The lentiviral vector was lysed using the 
detergent 0.5% Igepal-20 following a 10-fold serial 
dilution. They were compared to the standards by Q-PCR, 
giving a total virus genome count of 3 x 1011 per ml, which 
was 30,000-fold higher than the infectious titer.  
 
p24 assay: 
 The p24 protein is the HIV viral capsid protein, and 
it was assessed using enzyme linked immunosorbent assay. 
The quantity of p24 revealed a total virus genome count of 
2.7 x 1011 per ml, which was equivalent to the number 
obtained through by Q-PCR.  
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                   IV. DISCUSSION 
 
 The use of viral vectors for gene therapy has been 
studied widely. Viral vectors used in clinical trials, or 
in clinically infected animals, tend to distribute to non-
target organs, followed by shedding (Delenda & Gaillard, 
2005; Hackett et al., 2000; Heid, et al. 1996; Lizée et 
al., 2003). Although the vectors are generally safe, the 
potential risk of recombinant virus entering the 
environment needs to be assessed for proper biocontainment. 
Studies on the shedding of vector viruses are lacking in 
the scientific literature. In this study, a Q-PCR assay was 
developed to measure the amount of adenoviral and 
lentiviral vectors shedding from experimentally infected 
animals.  
 Adenoviral and retroviral vectors are the most 
commonly used vectors in gene therapy. The vectors in the 
current study were developed from commercially available 
kits. For Adenovirus, the infectious titer was determined 
by plaque assay and total virus genome count was determined 
by Q-PCR. From this, the ratio of total virus genome count 
(vg) to infectious viral particle count was calculated. 
This ratio reveals the quantity of dead or defective viral 
particles, which must be considered for any virus stock. 
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Noninfectious particles will contribute to the number of 
particles being shed from an animal. 
In the current study, the adenoviral vector gave 
vg:pfu values of 12:1 and 5:1 for each of two stocks. 
Diaconu et al (2010) reported a similar ratio of 10:1 and 
4.7:1 for a similar Ad5-based vector. In general, a high 
quality batch of the adenoviral vector would have a ratio 
less than 30:1 (Ludewig & Hoffmann, 2005). 
For the lentiviral vector, the infectious titer was 
determined by colony forming unit (cfu) assay and total 
virus genome count was determined by Q-PCR. The ratio of 
vg:cfu for the lentiviral vector was 30,000:1, suggesting 
the presence of a large amount of defective particles. In 
general HIV genomes possess large proportion of defective 
viral particles and defective particles are mutants of the 
virus which might lack one or more gene (Bernier & 
Tremblay, 1995; Li et al., 1991). The total virus genome 
count was confirmed by measuring concentrations of p24 Gag 
protein using enzyme-linked immunosorbent assay. The p24 
assay revealed a vg:cfu ratio of 27,000:1. The correlation 
between viral titer and p24 protein has been studied. The 
p24 protein per particle number is converted to molecules 
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per virion by using a molecular weight of 2.4x 104 g mol-1 
(Layne et al., 1992). 
 The use of Real-time PCR for quantification of nucleic 
acids is an essential, powerful technique used in a wide 
range of analyses. Real-time PCR measures the amount of DNA 
produced in the exponential phase of amplification. In 
contrast, conventional PCR shows only the end-product of 
amplification, frequently in the plateau phase of 
amplification. This is why conventional PCR is not 
quantitative.  
For the quantitative PCR assay in the current study, 
primers and probes were designed to amplify and detect the 
encapsidation region of Adenovirus type 5 and the RRE 
region of HIV-1, strain NL4-3. Because all generations of 
adenoviral and lentiviral vectors to date retain these 
regions, the primers and probes designed here can be 
universally used, assuming the serotype or strain is 
similar.  
In order to assess the accuracy of the assay, the 
unknown sample is spiked with an internal control which 
helps the precise quantification. An external control that 
was amplified in a separate reaction would not be as 
accurate. A known number of molecules are added before the 
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processing of an unknown sample and during quantification, 
and it is co-amplified in a Q-PCR multiplex reaction. By 
using this strategy, the loss of sample during the 
processing is accounted for. The quality control sequence 
had minimal differences as compared to the wild type 
sequence to ensure similar efficiency for a comparable 
amplification. The primer binding regions remain the same 
for both wild type and quality control sequence. Saulnier 
et al (2003) reported the use of an internal control for 
adenoviral vectors in their study, but their control was λ 
bacteriophage for which primers and a probe were designed. 
 The quality control sequence to be spiked with the 
lentivirus was transcribed into RNA, which was then reverse 
transcribed into cDNA. The amplification curve was then 
compared to the curve for the DNA standards. In most cases, 
the efficiency of reverse transcription (cDNA synthesis) is 
often less than 100% and has been reported to be highly 
variable (Wong & Medrano, 2005). In the current study, cDNA 
was quantified using Q-PCR, and the efficiency of cDNA 
synthesis was found to be 20% on average. Since the genetic 
material of HIV-1 vector is RNA, it must be converted to 
cDNA for Q-PCR. Thus, this step is required, and the 
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conversion rate must be accounted for in the quantitative 
assay. 
With a minimal number of sequence differences in the 
probe region of the wild type sequence, a quality control 
sequence was designed to spike the unknown samples. 
Kawahira et al. (2010), in their study on viral shedding 
after adenoviral vector treatment for esophageal cancer, 
used conventional PCR to report only the positive or 
negative viral DNA in samples. The quantification of the 
sample was not performed to show the amount of virus the 
patient was shedding.  
In the current study, five 10-fold serial dilutions of 
the vector DNA of wild type and quality control sequence 
were performed in singleplex reactions and optimized along 
with their specific primers and probes. The multiplex 
format showed that the quality control sequence did not 
interfere with amplification of the wild type DNA. This 
multiplex format makes use of two assay templates with two 
different probes and a single set of primers. Saulnier et 
al (2003) made use of the similar principle but they used 
completely different assay sets. The multiplex reaction in 
the current study clearly showed high specificity and 
sensitivity, to which the viral shedding can be compared.  
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The standard curves for assessing the wild type and 
quality control sequences were generated using a dynamic 
range of 4 logs (106 to 102). The upper limit of this range 
was chosen based on the observation that Ct values were 
approaching the baseline Ct range (generally between cycles 
3 and 15). The lower limit of the dynamic range was chosen 
based on the observation that Ct values for the 102 standard 
were less than or equal to 37. Values of Ct between 37 and 
40 were defined as the equivocal range for this study. When 
limiting dilutions of DNA and RNA molecules for the 
adenoviral and lentiviral systems were performed and 
measured by Q-PCR, quantities below 10 (in the 37 to 40 Ct 
range) could be detected by extrapolation from the standard 
curve. The true limit of detection for viral shedding will 
be determined in future experiments using biological 
samples spiked with known amounts of virus. 
Conclusion and Future studies: 
 In conclusion, a highly specific, sensitive, and 
reproducible assay using Q-PCR to quantify the shedding of 
adenoviral and lentiviral vector viruses from excretions of 
experimentally infected animals was developed. Future 
studies will include testing for replication competent 
virus (RCV) in the virus stocks. A multiplex reaction 
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performed on biological samples spiked with wild type virus 
and quality control sequences will confirm the sensitivity 
of the assay. Finally, testing samples obtained from 
infected and control research animals will reveal how much 
virus is being shed by specific routes of infection using 
specific doses for virus for the initial infection. 
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                V. GLOSSARY 
BJ5183-AD-1: Electroporation competent bacterial cells 
cDNA: Complementary deoxyribonucleic acid 
CFU: Colony forming units 
Ct: Threshold cycle 
E1,E2,E3,E4: Early transcribed regions of adenovirus 
HIV-1: Human immunodeficiency virus-1 
PCR: Polymerase chain reaction 
PFU: Plaque forming units 
pShuttle-CMV-lacZ: Control shuttle vector 
QC: Quality control 
Q-PCR: Quantitative polymerase chain reaction 
R2: Coefficient of determination 
RRE: Rev response element 
Wt: Wildtype virus 
XL-10: Ultracompetent bacterial cells 
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